Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial (2019)
- Authors:
- Autor USP: NICOLAU, JOSÉ CARLOS - FM
- Unidade: FM
- DOI: 10.1161/CIRCULATIONAHA.119.039996
- Subjects: DIABETES MELLITUS NÃO INSULINO-DEPENDENTE; INFARTO DO MIOCÁRDIO; ANTIDIABÉTICOS (HIPOGLICEMIANTES); RESULTADO DE TRATAMENTO
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Publisher place: Philadelphia
- Date published: 2019
- Source:
- Título: Circulation
- ISSN: 0009-7322
- Volume/Número/Paginação/Ano: v. 139, n. 22, p. 2516-2527, 2019
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
FURTADO, Remo H. M et al. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial. Circulation, v. 139, n. 22, p. 2516-2527, 2019Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.039996. Acesso em: 10 jan. 2026. -
APA
Furtado, R. H. M., Bonaca, M. P., Raz, I., Zelniker, T. A., Mosenzon, O., Cahn, A., et al. (2019). Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial. Circulation, 139( 22), 2516-2527. doi:10.1161/CIRCULATIONAHA.119.039996 -
NLM
Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Nicolau JC. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial [Internet]. Circulation. 2019 ; 139( 22): 2516-2527.[citado 2026 jan. 10 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.039996 -
Vancouver
Furtado RHM, Bonaca MP, Raz I, Zelniker TA, Mosenzon O, Cahn A, Kuder J, Murphy SA, Bhatt DL, Nicolau JC. Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction Subanalysis From the DECLARE-TIMI 58 Trial [Internet]. Circulation. 2019 ; 139( 22): 2516-2527.[citado 2026 jan. 10 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.039996 - Oclusão de comunicação interventricular pós-infarto com prótese percutânea CERA
- Spontaneous MI After Non–ST-Segment Elevation Acute Coronary Syndrome Managed Without Revascularization: The TRILOGY ACS Trial
- Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
- Timing, Profile, and Predictors of Spontaneous Myocardial Infarction Following a Non-ST-Segment Elevation Acute Coronary Syndrome Event: Insights From the TRILOGY-ACS Trial
- The Efficacy and Safety of Low-Dose Rivaroxaban With or Without a Proton Pump Inhibitor: Insights From the ATLAS ACS 2-TIMI 51 Trial
- Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial
- Reduction in aubtypes and sizes of myocardial infarction with ticagrelor in PEGASUS-TIMI 54
- Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes
- P2Y12 inhibitor switching in response to routine notification of CYP2C19 clopidogrel metabolizer status following acute coronary syndromes
- Extent of coronary and myocardial disease and benefit from surgical revascularization in LV dysfunction
Informações sobre o DOI: 10.1161/CIRCULATIONAHA.119.039996 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
